Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
Biogen, 21 Oct 2015
Accessed on 27 Oct 2015 from http://media.biogen.com/press-release/corporate/biogen-reports-top-line-results-phase-3-study-evaluating-natalizumab-seconda.